Newer diabetes drugs cost more, but may not work better

February 28, 2014 by Nicole Casal Moore, University of Michigan

Two newer classes of drugs to treat adult-onset diabetes may be no more effective than the old standby, yet they cost significantly more over the course of a patient's disease.

That's according to a National Science Foundation-funded study by researchers at the University of Michigan, Mayo Clinic and North Carolina State University.

Based on a simulation model that involved 15 years worth of actual patient data from more than 37,000 individuals, the researchers found that the newer drugs cost patients and insurance companies anywhere from $1,600 to $2,400 more.

That's from the time a person is diagnosed until he or she develops heart problems, circulatory complications or dies. The exact time period varies widely, but it can be more than a decade.

Some 25 million Americans live with today, so the researchers say the findings offer an avenue for substantial savings.

"Conventional wisdom would suggest the newer medications should be more effective since they cost more, but what we find is that they don't appear to result in people living longer or avoiding complications," said principal investigator Brian Denton, U-M associate professor of industrial and operations engineering who specializes in medical decision-making.

The drugs they studied are the second line of defense when the body develops resistance to the gold standard medication known as metformin. At that point, doctors typically prescribe an additional pill to stave off daily insulin shots. While there are many different options, there's no consensus as to which work best.

The , developed by lead study author Yuanhui Zhang, a doctoral student at North Carolina State, compared the newer classes known as DPP-IV inhibitors and GLP-1 agonists with the older drug called sulfonylurea. They all have different mechanisms for stabilizing patients' blood sugar levels (DPP-IV inhibitors are marketed under the names names Januvia, Onglyza and Tradjenta; popular GLP-1 agonists include Byetta and Victoza).

In the years since the more modern drugs have been released, many doctors have shifted to prescribing them over the older sulfonylurea—partially because they don't have the risk of hypoglycemia and weight-gain side effects that sulfonylurea can have. But the shift is partially to blame for a rise in the cost of and management, the study shows.

"All of the medications that have been considered in the model have some risk and down sides that can impact a person's well-being," said Steven Smith, an endocrinologist at Mayo Clinic. "But our model can help to assess optimal decision-making that would take into account individual and unique risks for all medications, old and new."

Down the road, the researchers envision a tool that doctors themselves can use.

Simulations can provide a unique perspective that could in some ways model the real world better than a clinical trial, Denton said. Patients participating in a clinical trial may behave differently than they would otherwise, adhering to doctors' orders better.

Explore further: Linagliptin noninferior to glimepiride in type 2 diabetes

More information: Yuanhui Zhang, Rozalina G. McCoy, Jennifer E. Mason, Steven A. Smith, Nilay D. Shah, and Brian T. Denton. "Second-line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?" Diabetes Care published ahead of print February 26, 2014, DOI: 10.2337/dc13-1901 1935-5548

Related Stories

Linagliptin noninferior to glimepiride in type 2 diabetes

June 28, 2012
(HealthDay) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.

ACP recommends metformin to treat type 2 diabetes based on CE analysis of oral medications

February 6, 2012
The American College of Physicians (ACP) recommends that clinicians add metformin as the initial drug treatment for most patients with type 2 diabetes when lifestyle modifications such as diet, exercise, and weight loss have ...

Diabetes drugs taken by over 15 million Americans raises risk of bladder cancer

August 13, 2012
A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. Researchers from the Perelman School of Medicine ...

US probes new pancreas risks with diabetes drugs (Update)

March 14, 2013
The U.S. Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.

Computer simulation shows that knowing patients' genetic profiles can save money, improve outcomes

February 20, 2014
(Medical Xpress)—Genetic testing can help doctors choose the most effective and economical drugs to prevent blood clots in the half a million patients in the U.S. who receive coronary stents each year, according to a new ...

Recommended for you

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

Gene therapy restores normal blood glucose levels in mice with type 1 diabetes

January 4, 2018
Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.